[First experience in using cardiocytoprotector mexicor in operations of myocardial revascularization under conditions of extracorporeal circulation].
We examined a total of forty-four patients diagnosed with coronary artery disease who were subjected to coronary artery bypass graft surgery under conditions of extracorporeal circula tion. In the examined group (15 patients) during anaesthesia and perfusion, we additionally administered the cardiocytoprotector mexicor at a total dose of 1,500 mg. It was revealed that administering mexicor in a complex of anaesthesiological-and-resuscitation support considerably increased the indices of myocardial contractility and oxygen-transporting function of blood in the postperfusion period, also decreasing both the amount and duration of inotropic stimulation, and favourably contributing to early recovery and restoration of spontaneous respiration in the immediate postoperative period.
G A
GA
Boiarinov
Iu D
IuD
Brichkin
A V
AV
Bogush
N Iu
NIu
Mel'nikov
A Iu
AIu
Smorkalov
M A
MA
Belonogov
V V
VV
Pichugin
I V
IV
Spitskaia
E V
EV
Dudina
D001026:Coronary Artery Bypass / Q000379:methods*; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D004305:Dose-Response Relationship, Drug; D005112:Extracorporeal Circulation / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects* / Q000502:physiology; D011725:Pyridines / Q000008:administration & dosage*; D016896:Treatment Outcome
D011725:Pyridines; C517040:ethylmethylhydroxypyridine succinate